#ONS25

Make Cancer Less Shitty

@cancersuckless.bsky.social

10 months ago

We ♥️ meeting new people who are doing amazing things to #MakeCancerLessShitty & we met plenty of fabulous humans at #ONS25 last week! We shared stories, chatted about impacts of side effects & discussed the need to improve access to quality supportive care! Looking forward to #AACR25 & #ASCO25 too!

Dana-Farber News

@danafarbernews.bsky.social

11 months ago

Congratulations to Ijeoma Eche-Ugwu, PhD, MPH, FNP-BC, who has been recognized with the #ONS25 Victoria Mock New Investigator Award. She is the fifth @danafarbernews.bsky.social nurse scientist to receive the prestigious honor since 2003. bit.ly/43LYIQW

OncLive

@onclive.bsky.social

11 months ago

Retrospective Study Shows Variability of Interventions for Blinatumomab-Related Neurotoxicity in Hematologic Malignancies A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

Retrospective Study Shows Variability of Interventions for Blinatumomab-Related Neurotoxicity in Hematologic Malignancies #ONS25 #hematology www.onclive.com/view/retrosp...

OncLive

@onclive.bsky.social

11 months ago

Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma #ONS25 #mmsm #oncology www.onclive.com/view/daratum...

OncLive

@onclive.bsky.social

11 months ago

Educational Intervention Seeks to Decrease Barriers to Cancer Clinical Trial Enrollment Cancer clinical trial education is valuable and may promote current and future participation.

Education Intervention Seeks to Decrease Barriers to Cancer Clinical Trial Enrollment #ONS25 #oncology

www.onclive.com/view/educati...

OncLive

@onclive.bsky.social

11 months ago

Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma @oncologynursing #ONS25 @medicalcollegeofwi.bsky.social #mmsm #oncology
www.onclive.com/view/early-i...

OncLive

@onclive.bsky.social

11 months ago

Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC #ONS25 #pancsm #Oncology
www.onclive.com/view/antidia...

OncLive

@onclive.bsky.social

11 months ago

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration #ONS25 #oncology
www.onclive.com/view/multidi...

OncLive

@onclive.bsky.social

11 months ago

Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX #ONS25 #pancsm #oncology
www.onclive.com/view/timely-...

OncLive

@onclive.bsky.social

11 months ago

Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.

Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC #ONS25 #pcsm #oncology www.onclive.com/view/darolut...

OncLive

@onclive.bsky.social

11 months ago

Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC #ONS25 #kcsm #oncology www.onclive.com/view/subcuta...

OncLive

@onclive.bsky.social

11 months ago

Tailored Interventions Are Needed to Reduce Barriers to Breast Cancer Screening in Jordan A study identified individual and non-individual factors as barriers to breast cancer screening for women in Jordan.

Tailored Interventions Are Needed to Reduce Barriers to Breast Cancer Screening in Jordan #ONS25 #bcsm #oncology

www.onclive.com/view/tailore...

Dana-Farber News

@danafarbernews.bsky.social

11 months ago

#ONS25 kicks off today in Denver! Follow @danafarbernews.bsky.social for important research findings by @danafarber.bsky.social nurse scientists and clinicians highlighting clinical knowledge, research, patient care, advocacy and innovation. bit.ly/3XRA6SR